Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Biology

Epidemiology

Medicine

Microbiology

Internal Medicine

Show all topics

DOI

10.1016/s1473-3099(20)30731-3